Reviewer’s report

Title: A Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Assess the Efficacy and Safety of Emblica officinalis Extract in Patients with Dyslipidemia

Version: 1 Date: 31 May 2018

Reviewer: Tarun Belwal

Reviewer's report:

Abstract
1. conclusion need to be revised, more often it cover the result section.

2. some of the method discussed were not illustrated in the result section. For instance, HMG CoA reductase activity, etc.

3. line no 34..page 1...The serum levels of others...........placebo group, should be shifted to line 28.

4. full form of AIP and others must be mentioned

Background
1. line no 8...Identification of various......vascular disease, is a general statement which need to be deleted and change with appropriate concerning the prior sentence.

2. line 18 A lot of efforts.......change improve with diagnose...also remove prediction.

3. line no 21, 22,23.....ect. need to be cited with references. Kindly check sentences where references need to be added.

line 29...The adult treatment.....upto..line 34....tolerance of glucose need to be rephrase

4. the introduction need to be rephrase completely to show some story and link between the paragraphs. It should include studies that have been done on Amala on dyslipidemic clinical trial or in vivo or in vitro activity. What are the gaps and how your objective add on the existing objective. the objective need to be clearly define with its significance.

5. Introduction should contain: dyslipedemia, relation with atherosclerosis and other associated diseases, role of different enzymes and proteins in disease (with figure), role of medicinal plants. E. officinalis traditional value, in vitro, in vivo, clinical w.r.t. dyslipedemia, gaps in existing study and objective to add value.
method
1. the fist subsection should be on Plant extract

2. the fruit used is dried or fresh?

3. what is the quality attributes of roasted rice (any chemical analysis?)

4. Vitamin C is the major content of Amla, what % present in the extract?

5. wherever you have written supplementary file...add number also

Inclusion and Exclusion criteria
1. what is the diet chary? any specific in term of high fat, low fat diet?

2. patient taking any meditation or gym exercise?
   try to reduce the subsection under method section

general comments
1. replace additional file with supplementary file

2. page 12 line no 35.....four adverse events...what are those? kindly mention

Discussion
1. need complete reform
2. compared with statins...for that you can put some patients over statin treatment
3. focus more on how your study added new knowledge to the existing one

References
1. need to replace et al. with proper names.

Table 1 Amla extract should add Patient group under Amla extract treatment, same for placebo

Figure 3,4,5, 6 should be combined as one figure

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Unable to assess

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

the comments are below
I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal